Size, Share & Industry Analysis, By Product Format (Gels, Silicone Sheets and Tapes, Creams, Sprays and Oils), By Scar Application (Surgical Scars, Acne Scars, Burn and Trauma Scars), By Distribution Channel (Retail Pharmacies, Online Stores, Hospital and Clinic Dispensaries), By Active Formulation (Silicone-Based, Onion-Extract and Botanical, Moisturizing and Multi-Ingredient), and Global Forecast, 2026-2034
Explore the report section by section.
The global OTC Scar Treatment Products Market was valued at USD 3.37 billion in 2025, with USD 3.54 billion estimated for 2026 and USD 5.30 billion projected by 2034, equivalent to 5.2% CAGR over 2026–2034.
OTC scar-care sales include non-prescription silicone gels, reusable sheets, silicone sprays, onion-extract creams, emollient oils and targeted aftercare formulations purchased for closed surgical, burn, injury and acne-related scars. Dermatology injections, laser resurfacing, professional microneedling, prescription drugs and procedural fees are excluded. The American Academy of Dermatology identifies silicone sheeting and ointment as options for raised scars, while distinguishing scar prevention after wound closure from treatment of open skin injuries. A consumer can use silicone products for months, creating repeat-purchase demand in gels and replacement sheets.
U.S. plastic-surgery volumes sustain demand for postoperative silicone gels and incision dressings. The American Society of Plastic Surgeons counted nearly 1.6 million cosmetic operations in the United States in 2024, including 171,064 tummy tucks and 306,196 breast augmentations. Many patients seek inexpensive home care after incisions have closed, whereas clinicians reserve injections or revision surgery for more severe hypertrophic and keloid outcomes. ScarAway sells a combined gel-and-sheet kit, and Biodermis offers contoured silicone strips for breast and cesarean incisions, showing how brands match format to procedure and scar location.
Silicone is the most established OTC active platform for raised-scar management. M - lnlycke describes Mepiform as a flexible self-adherent dressing for hypertrophic and keloid scars, while Smith & Nephew markets CICA-CARE for softening and flattening elevated scars. Alliance Pharma offers KELO-COTE gel, spray and UV-protection versions; NewGel+ pairs silicone with vitamin E for visible skin sites. Products are generally applied after the wound has closed, and irritation or maceration can require interruption. Formulation differences therefore influence comfort, adherence, package size and retail pricing.
Consumer skincare products compete with medical-grade silicone on convenience and price. Mederma Advanced Scar Gel contains onion extract, allantoin, panthenol and hyaluronate; the manufacturer advises daily use for eight weeks on newer scars and three to six months on older marks. Bayer reported an eight-week BepanCare scar-gel study involving 55 people in 2026, while Bio-Oil publishes a randomized study of its skincare oil in 36 adult women. Such findings are product-specific rather than proof that all scar types respond equally; deep atrophic acne pits frequently require professional procedures.
Source: American Academy of Dermatology; American Society of Plastic Surgeons; World Health Organization; Bayer BepanCare 2026.
Non-prescription scar-management products are measured at product sales value for consumer use on healed skin; clinician procedures, prescription interventions and unrelated skincare are excluded.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million/billion |
| By Product Format | Gels; Creams and Ointments; Silicone Sheets and Tapes; Sprays and Oils |
| By Scar Application | Surgical Scars; Acne Scars; Burn Scars; Traumatic Injury Scars; Other Raised Scars |
| By Distribution Channel | Retail Pharmacies; Online Stores; Hospital and Clinic Dispensaries; Beauty and General Retail |
| By Active Formulation | Silicone-Based; Onion-Extract and Botanical; Moisturizing and Barrier-Repair; Other Multi-Ingredient |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; United Kingdom; Germany; China; India; Japan; Brazil; Mexico; South Africa |
| Key Market Players | Perrigo Company plc; Smith & Nephew plc; M - lnlycke Health Care AB; Alliance Pharma plc; Stratpharma AG; Biodermis; NewGel+; Bayer AG; DERMA E; Fixderma India Pvt. Ltd.; Union Swiss (Bio-Oil) |
Included revenue covers retail purchases of silicone gels, self-adhesive sheets, tapes, spray-on silicone, botanical scar creams and scar-specific oils sold without a prescription. It does not include general sunscreen, unrelated acne medicines, clinician laser sessions, corticosteroid injections or cosmetic surgery. Products are used only after epithelial closure unless a distinct approved wound-care indication exists.
Each sale is allocated once by its primary retail format, intended scar application, channel of purchase and principal formulation. A silicone gel sold online for a surgical scar contributes to four separate analytical cross-sections but only one unit of market revenue. Professional hospital use is counted only when the product is dispensed as an OTC item; the treatment visit itself is excluded.
The category includes silicone products marketed as medical devices and cosmetic or skincare preparations marketed for scar appearance, subject to country-specific claims rules. Atrophic acne pits are distinguished from raised hypertrophic scars because silicone does not restore lost dermal volume. The product boundary therefore reflects marketed scar-care indications rather than an assumption of equivalent efficacy across scar types.
Drivers Impact Analysis*
| Market Drivers | Impact Rank | CAGR Contribution (%) | 2026–2028 | 2029–2031 | 2032–2034 |
|---|---|---|---|---|---|
| Postoperative demand for scar gels and reusable silicone dressings | High | +2.20% | High | High | High |
| Pharmacy and ecommerce access to scar-specific OTC products | High | +1.80% | High | High | High |
| Silicone product innovations for facial and mobile scar sites | Medium-High | +1.50% | Medium | High | High |
| Burn and trauma aftercare in emerging health systems | Medium | +1.20% | Medium | Medium | High |
| Others (cosmetic procedures, cesarean aftercare, sunscreen combinations) | Low | +0.90% | Medium | Medium | Medium |
Restraints Impact Analysis*
| Market Restraints | Impact Rank | CAGR Contribution (%) | 2026–2028 | 2029–2031 | 2032–2034 |
|---|---|---|---|---|---|
| Long treatment duration and low adherence to daily use | High | -0.90% | High | Medium | Medium |
| Consumer price sensitivity and low-cost cosmetic substitutes | Medium | -0.80% | High | High | High |
| Claims limitations for depressed acne scars and mature keloids | Low-Medium | -0.40% | Medium | Medium | Low |
| Others (contact dermatitis, misuse on open wounds, retail returns) | Low | -0.30% | Medium | Low | Low |
*CAGR contribution shows the percentage points each factor adds to or removes from the 5.2% CAGR for 2026–2034; driver contributions less restraint contributions equal the market CAGR. Period columns rate the strength of each factor in that window.
The American Society of Plastic Surgeons recorded nearly 1.6 million U.S. cosmetic surgical procedures in 2024, including 349,728 liposuction procedures and 171,064 abdominoplasties. Each incision creates a potential period of home scar care after the wound closes. ScarAway sells a 60–90 day gel-and-sheet regimen, while Biodermis offers contoured C-section strips for surgical lines. Reusable sheets reduce replacement frequency but require daily cleaning, whereas gels can be reapplied to mobile skin sites. Cosmetic and reconstructive activity therefore supports a recurring retail audience without requiring a prescription.
The American Academy of Dermatology states that silicone sheeting may reduce raised-scar size, hardness, redness and itching, and can be used after surgery to help prevent raised scars. Smith & Nephew markets CICA-CARE for hypertrophic and keloid lesions, while M - lnlycke offers Mepiform for closed wounds. Mederma separately states that its gel cannot fill an indented acne scar, although it may soften the edges. Clear differentiation between raised and atrophic scars helps pharmacies guide buyers toward suitable products and limits ineffective claims that can undermine consumer trust.
WHO estimates 180,000 burn-related deaths annually, with most occurring in low- and middle-income countries. It reports more than one million moderate or severe burns each year in India and substantial childhood injury in Bangladesh. Patients who survive deep burns can develop thickened scars requiring long courses of protective silicone dressings. KELO-COTE lists burns among its intended scar types, and Biodermis sells large sheets for extensive areas. Low purchasing power and limited specialty access restrain premium product uptake, making locally available gels and pharmacy advice important in emerging markets.
ScarAway recommends gel use twice daily for 60–90 days, while Mederma suggests once-daily use for eight weeks on new scars and three to six months on old scars. NewGel+ advises continuous wear and cautions against applying gel beneath silicone sheeting because adhesion can fail. Consumers who stop early or experience rash may not see the intended change in scar appearance, reducing repeat purchases. Long treatment courses also create price sensitivity, particularly where reusable sheets and small gel tubes compete with inexpensive cosmetic creams.
OTC gels and silicone sheets are not substitutes for treating infected, open or rapidly growing scars. ScarAway cautions against application to open or oozing wounds, and M - lnlycke advises removing Mepiform if rash or maceration occurs. AAD guidance distinguishes home silicone therapy from corticosteroid injections, laser treatment and surgery for complex scars. Manufacturers that describe realistic appearance improvements and specify wound-closure timing reduce misuse, while unsupported promises for deep acne pits or established keloids can increase returns and regulatory scrutiny.
Sources: American Academy of Dermatology; WHO; ASPS; ScarAway; M - lnlycke; Mederma.
Biodermis supplies Epi-Derm strips shaped for cesarean incisions, while NewGel+ sells breast-surgery kits and silicone dots for small biopsy scars. Smith & Nephew describes CICA-CARE as a conformable reusable sheet, and ScarAway sells tape that can be trimmed for joints and curved body areas. These formats give consumers alternatives to rigid dressings after closure. Reuse intervals vary: ScarAway sheets can be washed and worn for seven to ten days, while Biodermis says its Epi-Derm sheets may last two to three weeks with care. ScarAway and Biodermis compete on fit and comfort, which influence repeat purchases.
KELO-COTE markets a transparent silicone gel and an SPF30 UV version for exposed scars. NewGel+ also offers UV gel for the face, arms and hands, while ScarAway describes a self-drying water-resistant silicone gel that can be covered with makeup after drying. These features matter for people treating facial scars who cannot conceal bulky sheets at work. Sun protection is relevant because pigment changes can make scars more visible, particularly on frequently exposed skin. Multifunctional gels command a convenience premium but must still be applied to healed skin.
Mederma Advanced Scar Gel uses onion bulb extract, allantoin, panthenol and hyaluronate; DERMA E sells a scar gel alongside microdermabrasion skincare. Fixderma combines onion extract, centella, niacinamide and silicone in its Kelocepa product. These formulations address buyers seeking a lightweight cream or gel rather than adhesive sheeting. Evidence varies by formulation and scar type, so brands increasingly provide ingredient lists and usage instructions. Pharmacy staff can distinguish cosmetic appearance care from treatments intended for raised hypertrophic scars, where silicone remains the better-established option.
ScarAway offers elongated sheets designed for C-section scars and a pediatric silicone gel, while Biodermis markets C-strips for abdominal incisions. The AAD advises applying silicone only after closure, which matters when consumers buy products before discharge. Pediatric products emphasize gentle application and explicit age guidance rather than strong active ingredients. A parent may prefer a small gel tube for facial injuries, whereas a post-cesarean buyer needs a long flexible strip that stays under clothing. Such segmentation increases the range of stocked products without changing the underlying scar-management indication.
Bayer described a 55-person eight-week open-label study of BepanCare silicone and dexpanthenol gel in 2026, reporting a 23.7% improvement in a scar assessment score. Bio-Oil publishes an eight-week placebo-controlled scar appearance study involving 36 women. Neither design demonstrates universal benefit across all scar categories, and consumers must follow product-specific instructions. Manufacturers publishing study limitations, time-to-improvement ranges and contraindications can reduce unrealistic expectations. This is particularly important for older scars, where longer courses and referral to dermatology may be necessary.
The OTC Scar Treatment Products Market spans gels, creams and ointments, silicone sheets and tapes, and sprays and oils. Each format differs in wear time, application area and replenishment economics. The AAD describes silicone sheets as effective options for raised scars, while ScarAway and KELO-COTE provide alternative topical formats for patients who cannot wear adhesive sheets during the day.
Gels represented an estimated ~47% of 2025 revenue. Silicone gels can be applied to facial and irregular surfaces and typically dry clear. ScarAway recommends a thin layer twice daily; KELO-COTE offers gel in multiple tube sizes. Small packaging encourages frequent replenishment and allows consumers to trial products at lower initial cost. Mederma and DERMA E extend the format with non-silicone active ingredients.
Silicone sheets and tapes serve longer linear incisions and raised scars. Smith & Nephew CICA-CARE and M - lnlycke Mepiform are used after wound closure; Biodermis offers larger sheets for burn areas. Mepiform and Epi-Derm require secure adhesion and cleaning for longer wear duration. Reusability can reduce expenditure per day but limits convenience on hair-bearing skin or joints.
Mederma creams and Bio-Oil skincare oil compete through texture and moisturizing benefits. KELO-COTE spray targets difficult-to-reach scars, while silicone ointments offer a transparent option when a sheet is impractical. Cream and oil buyers may have broader appearance concerns than users of raised-scar medical dressings.
Across 2026–2034, gels should remain the highest-value format, with sheets defending clinical positioning for hypertrophic scars. Convenience-driven sprays and UV-protective gels can gain shelf space where buyers value quick application and visible-site use.
Application categories separate surgical incisions, acne scars, burns, traumatic injuries and other raised scars. Product suitability differs materially between hypertrophic scars and depressed acne pits. Surgical patients often begin silicone after suture removal, while acne buyers may need professional treatment for structural tissue loss.
Surgical scars represented an estimated ~41% of 2025 revenue. The 2024 ASPS data recorded 306,196 breast augmentations and 171,064 abdominoplasties in the United States, both associated with incision aftercare. ScarAway C-section sheets and NewGel+ breast kits address these predictable treatment areas. Retail sales depend on surgeon advice, closure timing and patients continuing treatment after discharge.
Acne-related marks drive consumer search traffic and retail interest, but not all acne scars respond to topical therapy. Mederma states that its gel can smooth edges of indented scars without filling lost tissue. Silicone products such as ScarAway Acne Gel are aimed at raised acne scars rather than deep ice-pick lesions. Dermatology referrals remain important when pits or severe textural defects dominate.
WHO documents a substantial burden of burn injury in India and Bangladesh. Large silicone sheets and flexible dressings are used for healed raised burn scars, while smaller gels are convenient for traumatic cuts on exposed skin. Repeated replacement and affordability can constrain treatment continuity in low-income settings.
Procedure-linked purchasing should support surgical scar leadership, while acne and trauma products add a younger consumer audience. Clinical guidance on scar type will remain essential because appearance improvements vary by depth, age and location.
Retail pharmacies, online stores, hospital and clinic dispensaries, and beauty/general retail provide distinct purchase pathways. The consumer usually pays directly, so brand visibility, package size and product instructions influence selection. Clinicians may recommend silicone but the subsequent purchase frequently occurs outside the treatment facility.
Retail pharmacies account for the largest revenue pool because scar gels and dressings are available without a prescription. Mederma and ScarAway are marketed for self-care, and pharmacist advice can clarify that products should not be applied to open wounds. Pharmacy shelving also enables buyers to compare silicone sheets with botanical creams and select a price point suitable for several weeks of treatment.
Ecommerce supports recurring orders of replacement sheets and gel tubes. ScarAway, NewGel+ and Biodermis maintain product pages with size options and application instructions, helping buyers identify formats for specific body sites. Digital retail also creates opportunities for smaller silicone specialists that lack nationwide pharmacy distribution. Consumer reviews influence purchasing but do not replace clinical efficacy evidence.
Plastic-surgery clinics and burn centers may dispense silicone sheets after incision closure and provide fitting advice. Smith & Nephew and M - lnlycke offer professional wound-care products with scar-management indications. Direct dispensing captures a smaller share of OTC sales but influences later pharmacy and online replenishment through clinician recommendations.
Pharmacy leadership should persist through 2034, while online channels capture convenience-driven replenishment. Clinic recommendations will remain valuable for correct selection after surgery and for recognizing cases needing professional intervention.
The formulation split separates silicone-based products, onion-extract/botanical preparations, moisturizing barrier-repair formulations and other multi-ingredient combinations. These groups describe the principal functional ingredient rather than the package format. A silicone sheet and a silicone gel therefore belong to the same formulation category despite differing physical forms.
Silicone-based products form the largest formulation group because medical organizations recognize their role in raised scar care. Mepiform, CICA-CARE, KELO-COTE and ScarAway use silicone barriers to support hydration and reduce discomfort. The AAD notes that sheets may work better than ointment for some raised scars, but regular use over months is required. CICA-CARE and Mepiform product designs emphasize adhesion, breathability and daily wear time.
Mederma Advanced Scar Gel contains Allium cepa onion extract and allantoin, while Fixderma includes centella and niacinamide in scar-focused formulations. These products appeal to consumers seeking topical cosmetic care for discoloration and mild textural concerns. Manufacturer instructions recommend long courses; clinical results cannot be generalized from one ingredient combination to another.
Bio-Oil markets a skincare oil for new and old scar appearance, and Bayer combines silicone with dexpanthenol in BepanCare. Moisturizing products can reduce dryness and improve skin comfort after closure, although they do not replace treatment for severe keloids or atrophic pits. Combination products compete through feel, scent and compatibility with sunscreen.
Silicone should retain the strongest clinical positioning, while botanical and barrier-repair products broaden the retail audience. Evidence-backed ingredient claims and irritation warnings will matter more as formulations become complex.
North America leads 2025 sales value because pharmacies, online retailers and aesthetic clinics carry established silicone brands. European wound-care manufacturers provide advanced sheets, while Asia-Pacific demand benefits from surgical aftercare and rising access to dermatology. WHO injury data and clinician advice point to affordability constraints on long scar-care courses.
North America represented an estimated ~38% of 2025 revenue from OTC scar products. The United States has extensive pharmacy distribution for ScarAway and Mederma and a large base of cosmetic and reconstructive procedures. ASPS counted nearly 1.6 million cosmetic surgeries in 2024, with abdominoplasty and breast operations providing predictable post-incision aftercare needs. Specialty brands such as NewGel+ and Biodermis sell contour-specific silicone strips online, while clinical suppliers offer reusable sheets for raised scars. Buyers can switch among gels, creams and sheets without prescriptions, so adherence guidance and package economics shape retention. Canadian demand is supported by community pharmacies and postoperative self-care, although premium silicone products face private-pay sensitivity. Clinical guidance emphasizes that silicone begins only after wound closure and that depressed acne scars may require procedures rather than topical products. ScarAway product directions also require dry intact skin and regular cleaning before applying replacement sheets.
ASPS reported 349,728 liposuction procedures and 171,064 tummy tucks in 2024, alongside 306,196 breast augmentations. ASPS surgical volumes create incision-care opportunities once wounds have closed after surgery. ScarAway markets silicone gels and sheets for surgery, while Biodermis offers C-section and breast-specific strips. Dermatology guidance cautions that sheets can irritate skin if worn continuously without monitoring, so patient instructions influence use and refill rates.
Source: ASPS.
Europe has a substantial wound-care manufacturing base and structured community-pharmacy channels. M - lnlycke supplies Mepiform soft silicone dressings for hypertrophic and keloid scars, while Alliance Pharma markets KELO-COTE gels, sprays and UV formulations. Bayer introduced evidence from an eight-week BepanCare scar-gel study in 2026, adding an ingredient combination of silicone and dexpanthenol to the product mix. European buyers encounter different rules for medical-device claims and cosmetic products, encouraging brands to distinguish scar management from broader skin appearance care. The UK market features pharmacist-accessible silicone products and clinician advice on postoperative timing. Germany provides a clinical evidence base for topical aftercare and premium products, though treatment duration and price can limit repeat purchase. Mature pharmacy infrastructure supports brand competition, while ecommerce improves access to specialty sheet sizes not always stocked locally. Mepiform can be trimmed to fit closed scars, helping clinicians select a practical size for the treatment area.
Bayer described a 55-person prospective, open-label BepanCare study in August 2026, involving adults and children aged three or older with immature hypertrophic scars. Eight weeks of twice-daily application improved the POSAS score by 23.7%, but the study lacked a control group. The result supports product-specific clinical discussion rather than universal efficacy claims for scar creams, and pharmacies can use the design limitations when advising consumers.
Source: Bayer.
Asia-Pacific combines large populations, increasing surgical volumes and uneven access to specialist scar care. WHO estimates more than one million moderate or severe burn injuries annually in India, creating a large potential population needing post-healing scar management. Local pharmacy and ecommerce platforms distribute silicone gels and botanical products at multiple price points, while imported professional sheets remain costly for many buyers. China has a growing medical-device manufacturing base and consumer skincare sector; Japan emphasizes product quality, clear instructions and hospital-linked recommendations. South Asian demand also includes pediatric burns and trauma, where long-term follow-up is often difficult. Premium silicone sheets can be reused, but hygiene, fit and replacement intervals are important when household budgets are constrained. Regional expansion therefore depends on accessible pack sizes and practical patient education, not solely on new cosmetic formulations. WHO also reports that non-fatal burns create prolonged hospitalization and disability, strengthening the case for rehabilitation after acute care.
WHO reports more than one million moderate or severe burns each year in India, with many survivors facing long rehabilitation and scar-care needs. Fixderma markets silicone and botanical scar gels domestically, while Smith & Nephew CICA-CARE is available through professional and retail channels. Lower-cost gel tubes may be easier to sustain than large imported silicone sheets, particularly where specialist follow-up and reimbursement are limited.
Source: WHO.
Latin America has a developing market for scar-focused self-care across urban pharmacies, dermatology clinics and online beauty retailers. Silicone dressings and gels are relevant after elective surgery and traumatic injuries, while botanical scar creams compete in lower-price channels. Imported medical-grade products can be expensive when local currencies weaken, favoring smaller pack sizes and domestically distributed alternatives. Consumers with raised scars may benefit from professional advice about duration and fit, whereas depressed acne scarring is less responsive to OTC topicals. Brazil has a large private dermatology and cosmetic-surgery ecosystem, creating opportunities for post-procedure aftercare sales. Mexico adds demand through community pharmacies and general retail, but clinical product education varies across regions. The same consumer may buy a cream first and later switch to silicone sheeting if a raised scar persists, so accurate indications help prevent unsuitable purchases.
The American Society of Plastic Surgeons identifies silicone as a common postoperative scar-management option, while product suppliers such as KELO-COTE offer gels and sprays that can be applied after closure. In Brazil, urban private clinics and pharmacy networks provide a route for home-care products following surgery. Imported sheets face price competition from creams and oils, and scar location influences whether buyers prefer transparent gels or adhesive dressings.
Source: Alliance Pharma.
Middle East and Africa includes high-income Gulf retail markets alongside health systems with substantial burn and trauma burdens. WHO states that most burn deaths occur in low- and middle-income countries and that nearly two-thirds are in its African and South-East Asia regions. Patients in lower-resource settings may have limited access to specialist follow-up or several months of premium silicone sheeting. Gulf consumers can obtain imported gels, UV-protective formulations and branded scar products through private pharmacies and cosmetic clinics. Sun-exposed scar sites create demand for protective topical formats, although sunscreen and silicone serve different functions. In sub-Saharan Africa, basic wound closure and infection prevention take priority before any cosmetic scar treatment. Affordable post-healing products, practical instructions and community pharmacy distribution could expand access, while high prices and poor continuity of care constrain premium sales. ScarAway cautions against using silicone on open wounds, a critical distinction where delayed healing and infection remain common.
WHO identifies non-fatal burns as a cause of long-term disability and disfigurement in lower-resource health systems. After healing, silicone gels and sheets may help selected raised scars, but clinicians must first confirm intact skin and absence of infection. Retail availability and the need for weeks of consistent use make price a major barrier. KELO-COTE and similar imported products compete with lower-cost emollients in private pharmacies.
Source: WHO.
Competition spans large consumer-health owners, specialist silicone manufacturers and medical wound-care companies. Perrigo participates through ScarAway and Mederma, while Smith & Nephew and M - lnlycke serve clinical scar-management channels. Brand differentiation depends on the scar type, gel or sheet format, evidence and ability to sustain treatment over several months.
ScarAway markets silicone gel, tape and sheets; Mederma sells onion-extract scar gels with distinct directions for new and old scars. DERMA E targets acne-related appearance concerns, while Bio-Oil positions its skincare oil for both newer and older scars. Mederma and ScarAway rely on retail visibility and familiar gel formulations for replenishment.
CICA-CARE and Mepiform address hypertrophic and keloid scars through reusable or flexible silicone dressings. Their professional wound-care presence supports clinician recommendations, particularly after surgery and burns. Adhesion, comfort and rash precautions distinguish these products from generic cosmetic creams.
KELO-COTE offers transparent gels, sprays and UV products; Strataderm is a once-daily silicone gel for closed scars; Biodermis sells Epi-Derm sheets in multiple shapes. These firms compete on scar-site coverage and practical wear guidance rather than broad consumer advertising alone.
Bayer combines silicone and dexpanthenol in BepanCare, NewGel+ adds vitamin E to silicone gel, and Fixderma blends silicone with botanical ingredients. Ingredient differentiation can improve product feel and shelf appeal, but efficacy statements need to reflect each formulation’s supporting evidence.
Silicone remains the most clinically recognizable product platform, yet the customer may prefer an onion-extract gel when treating discoloration or a lightweight oil for daily skincare. Smith & Nephew positions CICA-CARE for red and raised scars, whereas Mederma states that its gel does not fill depressed acne pits. These different claims reduce direct substitution between product categories and reward brands that explain which scars can reasonably improve with OTC use.
Biodermis and NewGel+ compete through contoured silicone products for postoperative incision geometry. Biodermis markets large sheets for burns, shaped strips for cesarean incisions and facial applications, while NewGel+ offers dots and breast-surgery kits. ScarAway sells sheets that can be washed for repeated wear, and KELO-COTE offers spray for sensitive or difficult-to-reach areas. Such portfolios allow specialist suppliers to serve both clinic recommendations and consumer replenishment.
Bayer reported a 23.7% change in a scar assessment score after eight weeks of BepanCare use in a 55-person open-label study in 2026. Bio-Oil publishes a smaller randomized trial in adult women. Comparative clinical evidence remains uneven across brands and scar types, making the design of each study important for pharmacy claims. Brands with clear usage warnings can reduce dissatisfaction caused by application on unhealed wounds or severe scars requiring specialist care.
August 2026: Bayer published results from a 55-participant eight-week study of BepanCare scar gel, reporting a 23.7% improvement in a scar assessment score. Bayer formulated BepanCare with silicone and dexpanthenol for raised-scar aftercare. The company identified the investigation as a prospective, open-label, single-arm study, so the result should not be treated as proof of superiority over other silicone products. Source
June 2025: The American Society of Plastic Surgeons released its 2024 procedure statistics, reporting nearly 1.6 million cosmetic operations in the United States. The data included 171,064 abdominoplasties and 306,196 breast augmentations. The sustained volume supports demand for non-prescription scar gels and sheets once surgical incisions close, particularly through clinics and pharmacy aftercare recommendations. Source
2026: Stratpharma maintained its Strataderm professional scar-therapy portfolio, describing a once-daily silicone gel that dries to a transparent waterproof film. The product is indicated for old and new closed scars, including hypertrophic and keloid forms. Its once-daily schedule differs from competing twice-daily gels and provides a convenience option for consumers with adherence difficulties. Source
2025: M - lnlycke continued offering Mepiform, a flexible self-adherent soft-silicone dressing for old and new hypertrophic and keloid scars. The product can also be used after closure to help prevent raised scarring. Its Safetac contact layer is designed to reduce skin trauma on removal, supporting use where repeated dressing changes would otherwise cause discomfort. Source
2025: ScarAway expanded consumer choice across silicone scar sheets, gel, tape and acne-focused formulations, with directions specifying use only on intact skin. Its combined kit alternates sheets and gel rather than applying them simultaneously. The assortment shows how consumer brands are matching silicone products to scar geometry, daytime appearance and the practical needs of long treatment courses. Source
Global OTC scar-product revenue is forecast to rise from USD 3.54 billion in 2026 to USD 5.30 billion by 2034, representing 5.2% annual growth. Demand will be shaped by postoperative care, consumer preference for non-invasive products and the ability of brands to maintain use over multiple months.
| Forecast Variable | 2026 Starting Point | 2034 Commercial Effect |
|---|---|---|
| Product format | Gels lead revenue | Transparent gels retain value leadership; sheets defend raised-scar indications |
| Clinical application | Surgical aftercare largest | Incision care grows with cosmetic and reconstructive procedure volumes |
| Distribution | Pharmacies dominant | Ecommerce gains repeat gel and sheet purchases |
| Formulation | Silicone most established | Botanical and combination products compete on texture and price |
| Geography | North America largest | Asia-Pacific gains volume with wider pharmacy availability |
Surgical aftercare will remain the largest application because operations create identifiable incision sites and physicians can recommend silicone once closure is complete. ASPS data for 2024 show substantial U.S. demand for breast procedures, abdominoplasty and other operations associated with visible scars. Products sized for abdominal and breast incisions should continue to sell through clinics and online stores. ScarAway C-section sheets, NewGel+ breast kits and Biodermis contoured strips illustrate the value of tailoring the physical product to the wound location.
Gels will retain a convenient position for faces, joints and exposed skin. KELO-COTE markets UV gel with SPF30, while ScarAway offers a transparent self-drying silicone gel. NewGel+ provides vitamin E combinations and specialist sheet shapes, and Strataderm emphasizes once-daily use. These features can support premium pricing where buyers prioritize ease of application. Reusable silicone sheets should continue to appeal to people treating raised scars over months, but cleaning requirements and occasional irritation can limit adherence.
North American pharmacy access and high procedure volumes will support the largest revenue share, whereas Asian and African health systems face more pronounced affordability barriers. WHO reports a substantial burn-injury burden in India and low-income regions, which creates a clinical need for aftercare but not necessarily the ability to buy imported products. Smaller pack sizes, locally supplied gels and clear patient instructions could improve continuity. Consumers with severe keloids or depressed acne scars will still need assessment for procedures beyond OTC products.
Clinical evidence and realistic claims will influence competitive share through 2034. Bayer published an eight-week BepanCare study in 2026, while AAD guidance continues to distinguish silicone therapy for raised scars from interventions such as corticosteroid injections. Companies that explain wound-closure timing, wear duration and contraindications can reduce inappropriate use and build pharmacist confidence. Price-sensitive shoppers will continue comparing silicone sheets with onion-extract creams and oils, making product-specific evidence and treatment convenience central to differentiation.
Coverage addresses non-prescription scar-management products, their ingredients, retail pathways and scar indications in five regions.
The worldwide OTC Scar Treatment Products Market reached USD 3.37 billion in 2025 and is estimated at USD 3.54 billion in 2026. Revenue is projected to reach USD 5.30 billion by 2034. Included products are non-prescription scar gels, silicone sheets, tapes, creams, sprays and oils for healed skin, excluding clinical procedures.
The forecast CAGR is 5.2% from 2026 through 2034. Postoperative home care, silicone formulation options and pharmacy availability support growth, while multi-month treatment courses and price-sensitive consumers limit repeat purchasing. Silicone is generally used after wound closure, so treatment timing and adherence influence realized demand.
Silicone gel sheets and topical silicone are established options for raised hypertrophic scars, according to the American Academy of Dermatology. Sheets may perform better than ointment for some patients, but regular wear is needed for months. Keloids, painful scars and rapidly changing lesions should be assessed by a dermatologist rather than treated solely at home.
No topical gel reliably fills deep atrophic acne pits because those lesions involve loss of dermal tissue. Mederma notes that its gel may soften edges without filling an indented scar. Raised acne scars can respond differently to silicone, while ice-pick and rolling scars may require professional treatments such as resurfacing or subcision.
North America is the leading region, representing an estimated ~38% of 2025 revenue. The United States has extensive pharmacy distribution for ScarAway and Mederma and a large cosmetic-surgery base. The American Society of Plastic Surgeons reported nearly 1.6 million cosmetic operations in 2024, creating sustained postoperative aftercare demand.
ScarAway and Biodermis specify different wear times for their silicone sheet products. ScarAway advises at least 12 hours daily for its sheets, with gradual increases and a typical 60–90 day treatment course. Biodermis describes washable sheets that can last two to three weeks with proper care. Apply only to intact healed skin and stop if rash or irritation develops.
Silicone scar products should generally begin only after the incision is fully closed and sutures or scabs are no longer present. ScarAway, NewGel+ and M - lnlycke give warnings against application on open or oozing wounds. A surgeon may adjust timing for complications, infection, fragile skin or areas exposed to friction.
Silicone sheets have a more established role in managing raised hypertrophic and keloid scars, according to dermatology guidance. Onion-extract products such as Mederma offer a convenient topical alternative for appearance care, but efficacy differs by scar type. Choice also depends on adhesion, skin sensitivity, application site and the ability to continue treatment.
Suppliers include Perrigo through Mederma and ScarAway, Smith & Nephew through CICA-CARE, M - lnlycke through Mepiform, Alliance Pharma through KELO-COTE and Stratpharma through Strataderm. Biodermis, NewGel+, Bayer, DERMA E, Fixderma and Bio-Oil provide additional silicone or cosmetic formulations for scar appearance.
Silicone products may help manage raised scars after a burn has healed, but they should not be applied to an open burn wound. WHO emphasizes immediate burn first aid and medical assessment for serious injuries. Large sheets from Biodermis and other suppliers are designed for post-healing scar management, often alongside specialist rehabilitation.
Common challenges include inconsistent daily use, skin irritation, unrealistic expectations for depressed scars and the cost of multi-month regimens. ScarAway recommends a 60–90 day course, while Mederma suggests three to six months for older scars. Products should be selected according to scar type, wound closure and professional advice.
Revenue is projected to reach USD 5.30 billion by 2034, supported by surgical aftercare, ecommerce and improved silicone formats. Gels should retain value leadership, while reusable sheets remain important for raised scars. Clinical evidence and realistic usage instructions will differentiate suppliers as consumers compare medical-grade silicone with lower-cost cosmetic alternatives.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.